Focused On-demand Library for Transcription factor MafA

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NHW3

UPID:

MAFA_HUMAN

Alternative names:

Pancreatic beta-cell-specific transcriptional activator; RIPE3b1 factor; V-maf musculoaponeurotic fibrosarcoma oncogene homolog A

Alternative UPACC:

Q8NHW3

Background:

Transcription factor MafA, also known as Pancreatic beta-cell-specific transcriptional activator, RIPE3b1 factor, and V-maf musculoaponeurotic fibrosarcoma oncogene homolog A, is pivotal in insulin gene expression. It synergizes with NEUROD1/BETA2 and PDX1, binding to the insulin enhancer C1/RIPE3b element and TRE-type MARE DNA sequences, crucial for glucose regulation.

Therapeutic significance:

MafA's malfunction is linked to Insulinomatosis and diabetes mellitus, diseases characterized by multicentric insulinomas, hyperinsulinemic hypoglycemia, and varying degrees of glucose intolerance. Understanding MafA's role could unveil new therapeutic strategies for these conditions.